Views & Analysis Patient power in Europe – more work to be done What the EMA and pharma can do to promote patient involvement in decision making.
News Brexit could delay drug launches, former MHRA chief warns Britain will be in "second or third tier" of drug launches, experts warn.
News Could UK's post-Brexit regulator evaluate value as well? But longer-term benefits could include faster reimbursement decisions.
News Hunt under pressure over plans to quit EMA Britain could be in "second rank" of medicines access, warn MPs.
News EU drug regulators concerned about Brexit impact European regulators concerned over impact of EMA move.
News Sanofi's Dupixent scores double COPD win in US, China Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.
Sales & Marketing Sponsored Shifting the paradigm in pharma marketing with content trans... Content transformation is changing pharmaceutical marketing. Join us to learn new strategies and approaches for this new world of patient centricity.